We are pleased to announce that CeGaT is the sequencing partner of CoMPaSS-NMD. The goals of this project are diagnosing neuromuscular disorders and developing personalized therapeutic pathways.
CoMPaSS-NMD – Computational Models for new Patients Stratification Strategies of Neuromuscular Disorders – is a project funded by the European Commission’s HORIZON EUROPE program. This initiative, led by the Italian University of Modena and Reggio Emilia, aims to develop innovative tools for more accurate and personalized diagnosis, monitoring, and treatment of patients affected by hereditary neuromuscular diseases (HNMDs). HNMDs often occur in young people, leading to long-term disability and early death. These conditions implicate a lack of participation and a need for permanent assistance and may require long-term institutionalization.
As a global provider of sequencing services, CeGaT has been selected to analyze the diagnostic samples and provide the sequencing data. Together with multiple clinical centers and industrial partners from various European countries, multidimensional data (clinical, genetic, histopathological, and MRI) will be processed and used to identify similar patient groups using high-dimensional computational tools.
As a primary outcome of the project, the CoMPaSS-NMD Atlas platform will be an AI-based application that will provide precise clinical characterization and diagnoses. Applying this patient-centered view can potentially increase the diagnostic rate of HNMD by 30% and promote effective actions by European national health systems.